Serum VEGF levels may have a role in the assessment of treatment response and disease activity during TNFi therapy in patients with axSpA
In patients with axSpA, TNFi therapy significantly reduces serum VEGF levels and effectively reduces disease activity. VEGF has the potential to function as a dynamic biomarker that reflects the characteristics of the disease and the response to treatment.
Authors
- Gökhan Kabadayi (ORCID: https://orcid.org/0000-0003-2076-3403)
- M. Ozmen
- Merve Güleç Yazır
- Leyla Didem Kozacı (ORCID: https://orcid.org/0000-0001-5422-1640)
- Kübra Kaya (ORCID: https://orcid.org/0000-0001-9937-5141)
- Dilek Solmaz (ORCID: https://orcid.org/0000-0001-6665-526X)
- Servet Akar
- Elif Durak Ediboğlu
Institutions
- Izmir Kâtip Çelebi University (TR)
- Ankara Yıldırım Beyazıt University (TR)
- Gazi University (TR)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1093/mr/roag004
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00